TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01007721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 671800 ED placebo
Description: 4 capsules of BI 671800 ED placebo (bid in the morning and evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 671800 ED placebo
Description: 4 capsules of BI 671800 ED placebo (bid in the morning and evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 ED 100 mg
Description: 2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 671800 ED placebo
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Study: NCT04454983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux System
Description: The iLux™ System is used to apply localized heat and pressure to a patient's eyelids. The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid. The iLux device allows view of the eyelid through a magnifier, then warms the eyelid to 40 to 42˚C, then force-limited compression is applied manually to express the melted meibum from obstructed glands. Warming is accomplished using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button. The force applied to the Compression Control is measured by a sensor in this mechanism.
Study: NCT04902638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of dexamethasone
Description: Intraarticular injection of dexamethasone
Study: NCT04821778

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50-66Gy/1.8-2.2Gy/25-30f

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: 50-66Gy/1.8-2.2Gy/25-30f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel based chemotherapy
Description: q1-3W according to physician's preference
Study: NCT04902638

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraarticular injection of dexamethasone
Description: Intraarticular injection of dexamethasone
Study: NCT04821778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel based chemotherapy
Description: q1-3W according to physician's preference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Anti-PD-1/PD-L1 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Analog based chemotherapy
Description: W1-5 qW or d1-14, q3W according to physician's preference

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU Analog based chemotherapy
Description: W1-5 qW or d1-14, q3W according to physician's preference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200-400mg, d1,qW
Study: NCT03488901

Intervention type: OTHER
Intervention: chemoresistance signature
Description: to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy

Intervention type: OTHER
Intervention: chemoresistance signature
Description: to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy

Intervention type: OTHER
Intervention: chemoresistance signature
Description: to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy

Intervention type: OTHER
Intervention: chemoresistance signature
Description: to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy

Intervention type: OTHER
Intervention: chemoresistance signature
Description: to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy

Intervention type: OTHER
Intervention: chemoresistance signature
Description: to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
Study: NCT03214562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04541134

Intervention type: DRUG
Group type: OTHER
Intervention: Pelubiprofen 45mg
Description: Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)

Intervention type: DRUG
Group type: OTHER
Intervention: Pelubiprofen 45mg
Description: Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
Study: NCT00504270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG3421 120mg
Description: 120mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG3421 20mg
Description: 20mg po daily
Study: NCT00588770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03819491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: COQUN ORAL FORMULATION
Description: COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: COQUN ORAL FORMULATION
Description: COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
Study: NCT02199262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music intervention
Description: reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology
Description: reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminder
Description: Implementation of a reminder of guidelines of agitation diagnosis and management
Study: NCT03370653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odiparcil
Description: Investigational product: odiparcil 250 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odiparcil
Description: Investigational product: odiparcil 250 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odiparcil
Description: Investigational product: odiparcil 250 mg tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Comparator: placebo tablets similar to odiparcil 250 mg tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator: placebo tablets similar to odiparcil 250 mg tablets
Study: NCT03479372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Suspension
Description: PAN-90806 provided in single-use dropper bottles for topical ocular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Suspension
Description: PAN-90806 provided in single-use dropper bottles for topical ocular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Suspension
Description: PAN-90806 provided in single-use dropper bottles for topical ocular administration
Study: NCT03438162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
Study: NCT03343236

Intervention type: RADIATION
Intervention: Radiotherapy
Description: All patients will undergo radiotherapy or surgery, or combined modality treatment
Study: NCT01557413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nail
Description: the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locked plate
Description: the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
Study: NCT04027556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low dose CT contrast media - lean body weight
Description: CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose CT contrast media
Description: CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
Study: NCT03725644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-training program
Description: Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional program
Description: Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
Study: NCT02102087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Specimen Diversion Device (ISDD)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lab standard practice (LSP)
Study: NCT04656626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief mindfulness based intervention
Description: The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Progressive muscle relaxation
Description: Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone.
Study: NCT03359265

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: underpants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: underpants
Study: NCT04902638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of dexamethasone
Description: Intraarticular injection of dexamethasone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraarticular injection of dexamethasone
Description: Intraarticular injection of dexamethasone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of dexamethasone
Description: Intraarticular injection of dexamethasone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraarticular injection of dexamethasone
Description: Intraarticular injection of dexamethasone
Study: NCT01726907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic SMG resection
Description: The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
Study: NCT03892785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone treatment
Description: tapering prednisone regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Description: tapering prednisone regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Description: Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate treatment
Description: Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: HAQ, SF-36, FACIT-fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: HAQ, SF-36, FACIT-fatigue

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Additionnal blood samples for immunomonitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Additionnal blood samples for immunomonitoring
Study: NCT01733056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine
Description: Administration of Fluzone (Influenza Vaccine)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Flu Vaccine
Description: Administration of Fluzone (Influenza Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine
Description: Administration of Fluzone (Influenza Vaccine)
Study: NCT01371331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: oral
Study: NCT01726907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic SMG resection
Description: An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson \& Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
Study: NCT01057966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)
Description: Single full strength dose capsule taken one time

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)
Description: Single half strength dose capsule taken one time
Study: NCT01107184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
Study: NCT04288908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyberball experimental task
Description: Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyberball experimental task
Description: Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
Study: NCT01791218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG, AVR or CABG+AVR and PVI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG, AVR or CABG+AVR
Study: NCT01920451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBTI)
Description: See arm description.
Study: NCT05141669

Intervention type: DRUG
Intervention: Fingolimod
Description: Participants who initiated fingolimod to treat multiple sclerosis (MS)
Study: NCT00696111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Lupron followed by estrogen plus placebo
Description: A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.